Medpace Holdings, Inc. $MEDP is Militia Capital Partners LP’s 7th Largest Position

Militia Capital Partners LP raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3,839.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,000 shares of the company’s stock after buying an additional 12,670 shares during the quarter. Medpace makes up approximately 3.1% of Militia Capital Partners LP’s portfolio, making the stock its 7th biggest position. Militia Capital Partners LP’s holdings in Medpace were worth $3,961,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Inspire Investing LLC purchased a new stake in Medpace in the first quarter valued at approximately $2,059,000. Strs Ohio purchased a new stake in Medpace in the first quarter valued at approximately $10,055,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Intech Investment Management LLC lifted its stake in Medpace by 61.1% in the first quarter. Intech Investment Management LLC now owns 21,354 shares of the company’s stock valued at $6,506,000 after buying an additional 8,097 shares during the last quarter. Finally, Capital Impact Advisors LLC purchased a new stake in Medpace in the first quarter valued at approximately $6,132,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $497.59 on Friday. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 37.00, a price-to-earnings-growth ratio of 3.00 and a beta of 1.44. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The stock’s fifty day moving average is $426.07 and its two-hundred day moving average is $348.17.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the prior year, the company earned $2.75 earnings per share. Medpace’s revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 36,196 shares of the company’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the company’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,266 shares of company stock valued at $74,111,427. Insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on MEDP shares. Mizuho boosted their target price on Medpace from $328.00 to $510.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Truist Financial boosted their target price on Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. Cowen lowered Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Finally, William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $422.27.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.